Mitsubishi UFJ Asset Management Portfolio holdings
AUM
$125B
1-Year Return
23.89%
This Quarter Return
-14.8%
1 Year Return
+23.89%
3 Year Return
+93.04%
5 Year Return
+163.06%
10 Year Return
+400.91%
AUM
$22.6B
AUM Growth
-$2.7B
(-11%)
Cap. Flow
+$1.53B
Cap. Flow
% of AUM
6.76%
Top 10 Holdings %
Top 10 Hldgs %
24.02%
Holding
1,238
New
87
Increased
775
Reduced
172
Closed
95
Top Buys
| 1 |
Apple
AAPL
|
$90.9M |
| 2 |
Microsoft
MSFT
|
$82.2M |
| 3 |
Amazon
AMZN
|
$46.5M |
| 4 |
Amgen
AMGN
|
$37.6M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
$30.1M |
Top Sells
| 1 |
Vanguard S&P 500 ETF
VOO
|
$23.9M |
| 2 |
AT&T
T
|
$18.4M |
| 3 |
Vanguard Intermediate-Term Treasury ETF
VGIT
|
$16.7M |
| 4 |
Baidu
BIDU
|
$14.8M |
| 5 |
CERN
Cerner Corp
CERN
|
$14.2M |
Sector Composition
| 1 | Technology | 24.32% |
| 2 | Healthcare | 14.31% |
| 3 | Financials | 11.76% |
| 4 | Consumer Discretionary | 10.46% |
| 5 | Communication Services | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
UBA
1026
DELISTED
Urstadt Biddle Properties Inc. Class A
UBA
| $236K | ﹤0.01% |
14,569
| – | – |
|
1027
Ginkgo Bioworks
DNA
$660M
| $233K | ﹤0.01% |
+2,448
| New | +$233K |
|
1028
Twist Bioscience
TWST
$1.55B
| $233K | ﹤0.01% |
6,652
+3,754
| +130% | +$131K |
|
1029
AbCellera Biologics
ABCL
$1.26B
| $233K | ﹤0.01% |
21,857
+5,849
| +37% | +$62.4K |
|
1030
Vericel Corp
VCEL
$1.72B
| $228K | ﹤0.01% |
9,047
+1,932
| +27% | +$48.7K |
|
1031
Olin
OLN
$2.9B
| $225K | ﹤0.01% |
4,853
-901
| -16% | -$41.8K |
|
1032
BioNTech
BNTX
$27B
| $224K | ﹤0.01% |
1,499
+415
| +38% | +$62K |
|
1033
Arcturus Therapeutics
ARCT
$485M
| $219K | ﹤0.01% |
13,915
+5,617
| +68% | +$88.4K |
|
1034
Inovio Pharmaceuticals
INO
$148M
| $219K | ﹤0.01% |
10,542
+6,805
| +182% | +$141K |
|
|
WSR
1035
Whitestone REIT
WSR
$672M
| $218K | ﹤0.01% |
20,240
| – | – |
|
|
ALX
1036
Alexander's
ALX
$1.2B
| $216K | ﹤0.01% |
974
| – | – |
|
1037
Maravai LifeSciences
MRVI
$363M
| $216K | ﹤0.01% |
7,605
-861
| -10% | -$24.5K |
|
1038
BridgeBio Pharma
BBIO
$10.2B
| $211K | ﹤0.01% |
+23,265
| New | +$211K |
|
|
CLDT
1039
Chatham Lodging
CLDT
$363M
| $210K | ﹤0.01% |
20,063
| – | – |
|
|
SAFE
1040
DELISTED
Safehold Inc.
SAFE
| $209K | ﹤0.01% |
5,901
| – | – |
|
1041
Novavax
NVAX
$1.28B
| $208K | ﹤0.01% |
4,036
-14,074
| -78% | -$725K |
|
1042
Worthington Enterprises
WOR
$3.24B
| $207K | ﹤0.01% |
7,630
+54
| +0.7% | +$1.47K |
|
1043
Shell
SHEL
$208B
| $203K | ﹤0.01% |
3,883
-1,962
| -34% | -$103K |
|
1044
Roivant Sciences
ROIV
$8.82B
| $202K | ﹤0.01% |
+49,715
| New | +$202K |
|
|
BHIL
1045
DELISTED
Benson Hill, Inc.
BHIL
| $201K | ﹤0.01% |
+2,093
| New | +$201K |
|
|
VG
1046
DELISTED
Vonage Holdings Corporation
VG
| $190K | ﹤0.01% |
10,105
-4,971
| -33% | -$93.5K |
|
|
LX
1047
LexinFintech Holdings
LX
$1.02B
| $189K | ﹤0.01% |
84,700
+21,135
| +33% | +$47.2K |
|
1048
Repay Holdings
RPAY
$506M
| $186K | ﹤0.01% |
14,462
-1,143
| -7% | -$14.7K |
|
1049
Ligand Pharmaceuticals
LGND
$3.25B
| $185K | ﹤0.01% |
3,331
+918
| +38% | +$51K |
|
1050
Novo Nordisk
NVO
$245B
| $184K | ﹤0.01% |
3,304
-2,456
| -43% | -$137K |
|